Stryker Co. (NYSE:SYK) Shares Bought by DnB Asset Management AS

DnB Asset Management AS lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 4.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 63,002 shares of the medical technology company’s stock after acquiring an additional 2,971 shares during the period. DnB Asset Management AS’s holdings in Stryker were worth $22,684,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new stake in Stryker in the third quarter worth about $317,000. Townsquare Capital LLC lifted its stake in shares of Stryker by 11.9% in the 3rd quarter. Townsquare Capital LLC now owns 7,468 shares of the medical technology company’s stock worth $2,698,000 after acquiring an additional 792 shares during the period. CreativeOne Wealth LLC boosted its holdings in shares of Stryker by 46.8% in the third quarter. CreativeOne Wealth LLC now owns 2,078 shares of the medical technology company’s stock valued at $751,000 after acquiring an additional 662 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Stryker by 4.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,745,971 shares of the medical technology company’s stock valued at $630,749,000 after acquiring an additional 74,224 shares during the period. Finally, Financial Counselors Inc. raised its holdings in Stryker by 4.3% during the third quarter. Financial Counselors Inc. now owns 38,370 shares of the medical technology company’s stock worth $13,862,000 after purchasing an additional 1,593 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Down 0.9 %

SYK opened at $364.38 on Friday. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The business has a 50 day moving average of $384.08 and a 200-day moving average of $374.25. The stock has a market capitalization of $139.08 billion, a price-to-earnings ratio of 46.96, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period last year, the business posted $3.46 EPS. As a group, sell-side analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.92%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SYK shares. Barclays increased their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. JPMorgan Chase & Co. lifted their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. Stifel Nicolaus lifted their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Friday, March 21st. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $421.90.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.